Cara Therapeutics: Scratching An Itch Left Unscratched | Latest News RSS feed
Cara Therapeutics: Scratching An Itch Left Unscratched - Latest News
Cara Therapeutics: Scratching An Itch Left Unscratched
CARA therapeutics wholly owns its proprietary kappa opioid-receptor agonist, KORSUVA/CR845, and is targeting several largely underserved markets. Several catalysts are expected throughout the next yea... read more
Here's Why Cara Therapeutics Rose 12.5% in August
That jumbled mess of scientific words essentially means Cara Therapeutics is developing a drug to treat itching that arises in some patients ... high-risk pharma stock that's best left to investors wi... read more
Cara Therapeutics Is Scratching the Itch for Promising Biotechs
Micro-cap biotech Cara Therapeutics (NASDAQ: CARA) reported another in a string of positive trial results for its pain and itching drug, CR845. As the risk of failure for its only drug in human trials ... read more
Looking for another news?
Is Cara Therapeutics, Inc. a Buy?
An investment in the volatile Cara Therapeutics is essentially a bet on a single drug for pain, itching, and inflammation that the company has in human trials, CR845. The reliance on a single molecule ... read more
Forget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock
Cara Therapeutics' (NASDAQ: CARA ... Around 60% of all patients on hemodialysis experience the itching associated with CKD-aP. While Cara looks forward to potentially launching its first product over ... read more
Can Cara Ultimately Get Its Drug Approved?
Cara Therapeutics Inc. (NASDAQ: CARA ... showed that the primary endpoint of the Phase 2 trial was the change from baseline of the average worst itching during the second week of treatment, as recorde... read more
Cara Therapeutics shares pop on a lucrative licensing deal for its drug Korsuva
Shares of Cara Therapeutics (NASDAQ:CARA ... The agreement offers Vifor Fresenius the chance to sell Korsuva, Cara’s injectable drug for itching which results from kidney dialysis, most everywhere, ap... read more
Cara Therapeutics' (CARA) CEO Derek Chalmers on Q2 2016 Results - Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ:CARA ... The primary endpoint will be reduction in worst itching scores from baseline values, measured on a standard Numeric Rating Scale alongside secondary quantitati... read more
Here's Why Cara Therapeutics Jumped 56.5% in the First Half of 2018
Shares of Cara Therapeutics ... ceaseless itching that makes life miserable for a large portion of patients with chronic kidney disease who visit dialysis centers regularly. Image source: Getty Images ... read more
Does This New Partnership Make Cara Therapeutics Stock a Buy Now?
Cara Therapeutics couldn't have asked for a better partner, as practically all of Fresenius clients who suffer chronic itching could quickly become Korsuva customers. Fresenius recorded around $14.1 b... read more
What Happened in the Stock Market Today
The total 5,175,000 shares would represent a dilution of the stock by 15.8%. Cara Therapeutics is developing Korsuva, a drug for pruritus, or severe itching, and the proceeds will be used to advance i... read more